Background-Low plasma 25-hydroxyvitamin D [25(OH)D] levels are associated with high cardiovascular risk. This may be because that low 25(OH)D levels are associated with high levels of atherogenic lipoproteins, but whether these 2 risk factors are genetically associated is unknown. We tested this hypothesis. Methods and Results-Using a Mendelian randomization approach, potential genetic associations between plasma levels of atherogenic lipoproteins and 25(OH)D were examined in ≤85 868 white, Danish individuals in whom we genotyped for variants affecting plasma levels of 25(OH)D, nonfasting remnant cholesterol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol. Lipoprotein levels were measured in all and 25(OH)D levels in 31 435. A doubling in nonfasting remnant cholesterol levels was observationally and genetically associated with −6.0%(95% confidence interval [CI], −6.5% to −5.5%) and −8.9% (95% CI, −15% to −2.3%) lower plasma 25(OH)D levels. For low-density lipoprotein-cholesterol levels, corresponding values were −4.6% (95% CI, −5.4% to −3.7%) observationally and −11% (95% CI, −29% to +6.9%) genetically. In contrast, a halving in high-density lipoprotein-cholesterol levels was observationally associated with −1.5% (95% CI, −2.2% to −0.7%) lower but genetically associated with +20% (95% CI, +7.4% to +34%) higher plasma 25(OH)D levels. Plasma levels of lipoprotein(a) and 25(OH)D did not associate. Finally, low 25(OH)D levels did not associate genetically with levels of remnant and low-density lipoprotein-cholesterol. Conclusions-Genetically elevated nonfasting remnant cholesterol is associated with low 25(OH)D levels, whereas genetically reduced high-density lipoprotein-cholesterol is not associated with low 25(OH)D levels. These findings suggest that low 25(OH)D levels observationally is simply a marker for elevated atherogenic lipoproteins and question a role for vitamin D supplementation in the prevention of cardiovascular disease. (Circ Cardiovasc Genet. 2014;7:650-658.)
E pidemiological studies have reported that low circulating levels of 25-hydroxyvitamin D [25(OH)D], the most abundant form of vitamin D, are associated with high risk of ischemic heart disease and stroke. [1] [2] [3] This has been substantiated in recent meta-analyses. 4, 5 The exact mechanism underlying these associations, however, is unknown. A prevailing notion, supported by findings from cross-sectional studies, is that the association between low vitamin D and cardiovascular disease is related to a lipid-lowering effect of vitamin D. [6] [7] [8] These studies have generally shown an association between elevated atherogenic lipoproteins and low plasma 25(OH)D levels. 6, 7 However, corresponding findings from randomized trials with vitamin D supplementation have been conflicting, likely because of small sample sizes; differences in population characteristics; and in duration, dosage, and formulation of vitamin D supplementation. 7, [9] [10] [11] [12] [13] Therefore and because observational studies are highly susceptible to confounding and reverse causation, 14 it is unknown whether genetically low vitamin D levels are associated with elevated levels of atherogenic lipoproteins, or whether genetically elevated levels of atherogenic lipoproteins are associated with low vitamin D levels.
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The Mendelian randomization approach largely circumvents confounding and reverse causation because genetic variants are determined at random at conception and are constant through life. 14, 15 Therefore, genetic variants that are robustly associated with plasma levels of lipoproteins or 25(OH)D can be used as instrumental variables to test for the presence of potential genetic associations, that is, whether genetically elevated atherogenic lipoproteins is a likely determinant of low vitamin D, or whether genetically low vitamin D is a likely determinant of elevated atherogenic lipoproteins. Such knowledge is important to clinicians and the general population given the worldwide increasing consumption of nonprescription pharmacological doses of vitamin D in recent years. It is, nonetheless, noteworthy that the Mendelian randomization approach is not without limitations, which may arise when key assumptions for a genotype to be an instrument may not be plausible or when conventional linearity assumptions are not reasonable. 16 A conservative approach in the interpretation of a positive or a negative result using this approach is, therefore, generally prudent.
Using a Mendelian randomization design, we tested the hypothesis that genetically elevated atherogenic lipoproteins, that is, nonfasting remnant cholesterol and low-density lipoprotein (LDL) cholesterol, are associated with low plasma 25(OH)D levels in the general population, and the converse, whether genetically low plasma 25(OH)D levels are associated with elevated atherogenic lipoproteins. We also tested whether genetically reduced high-density lipoprotein (HDL) cholesterol is associated with low plasma 25(OH)D levels, and the converse, whether genetically low plasma 25(OH) D levels are associated with reduced HDL-cholesterol. Figure 1 outlines the study design. Briefly, each association was first explored in observational analyses that are predisposed to confounding and reverse causation (Figure 1, 1) , and then the corresponding genetic analysis using genetic variants as instruments that are generally thought to circumvent confounding and reverse causation was examined ( Figure 1, 2-3 ).
Methods
The studies were approved by Herlev Hospital and Danish ethical committees, and conducted according to the Declaration of Helsinki with all participants providing written informed consent. All participants were white and of Danish decent. None were included in >1 study or lost to follow-up.
The Copenhagen General Population Study
In this study, initiated in 2003 with ongoing enrolment, 17 participants of 20 to ≥100 years were randomly invited from the national Danish Central Person Register to reflect the general population. Data collection included a self-administered questionnaire, a physical examination, and blood sampling for biochemical analyses and DNA extraction. We included ≤25 682 participants with 25(OH)D measurements and ≤80 115 participants with lipoprotein measurements.
The Copenhagen City Heart Study
This study of the Danish general population initiated in 1976 to 1978 with follow-up examinations in 1981 to 1983, 1991 to 1994, and 2001 to 2003, 17 recruited and examined participants exactly as in The Copenhagen General Population Study (CGPS). We included ≤5753 participants with 25(OH)D and lipoprotein measurements.
Laboratory Analyses
Nonfasting plasma total cholesterol, triglycerides, HDL-cholesterol, and creatinine were measured fresh using standard hospital colorimetric assays (Boehringer Mannheim or Konelab). LDL-cholesterol was calculated using the Friedewald equation when plasma triglycerides were ≤4.0 mmol/L and otherwise measured directly (Konelab). Nonfasting remnant cholesterol was calculated as nonfasting total cholesterol minus HDL-cholesterol minus LDL-cholesterol, as done previously. [17] [18] [19] [20] Plasma lipoprotein(a), where levels are chiefly determined genetically and, therefore, unlikely to be influenced by vitamin D levels, were measured as described previously. 21 Plasma 25(OH)D was measured by the DiaSorin Liaison 25(OH)D TOTAL assay using plasma collected in 2004 to 2005 and 2009 to 2011 for the CGPS and plasma collected in 1981 to 1983 for The Copenhagen City Heart Study (CCHS), as described previously. 22 Assays were tested daily for precision and monthly for accuracy using a Scandinavian external quality control program.
Genotypes
Genotyping was performed using TaqMan (Applied Biosystems) or by restriction enzyme assays (details available from authors); the number of individuals genotyped for each assay vary according to when genotyping was performed. After a prespecified plan and on the basis of current evidence from published research, genotypes for 25(OH) D levels were carefully selected based on large effect sizes on plasma levels, but not through vitamin D-binding protein levels, as reported in genome-wide association studies. 23 Genetic variants around 7-dehydrocholesterol reductase (DHCR7) (rs7944926 and rs11234047) and cytochrome P450 R1 (CYP2R1) (rs10741657 and rs12794714) were thus selected. To act as an aggregate instrument for 25(OH)D levels, a simple allele score of 0 to 1, 2, 3, 4 to 5, and 6 to 8 25(OH)D-lowering alleles was constructed. The data for the white population from the HapMap project was used to assess whether the genotypes selected for 25(OH)D were in linkage disequilibrium with APOA5 rs651821, the only other variant in this study located on chromosome 11. Because of the role of DCHR7 in endogenous cholesterol synthesis and the role of CY2R1 might have in the metabolism of steroid hormones, the association of DCHR7 and CY2R1 allele scores with plasma cholesterol, cortisol, estradiol, and testosterone was also assessed.
Genotypes and allele scores for lipoprotein levels were likewise carefully selected on the basis of published research, as described previously. 18, 19 Genetic variants around lipoprotein lipase were excluded in this study based on the known associations of these variants with both nonfasting remnant cholesterol and HDL-cholesterol, as described previously. 18 Specifically, lipoprotein lipase genetic variants were found to be positively associated with nonfasting remnant cholesterol and inversely associated with HDL-cholesterol. 18 In addition, diseasecausing rare mutations together with single-nucleotide polymorphisms were selected for their large effect sizes on plasma lipoprotein levels and for being stronger instruments, as described previously. 18 Briefly, the genotypes (allele scores) for lipoproteins were combined into 3 groups: (1) nonfasting remnant cholesterol-increasing alleles (tribbles homolog 1 [TRIB1] rs2954029: negative regulator of retinoic acid receptor, glucokinase regulatory protein [GCKR] rs1260326: protein secreted by the liver that regulates triglyceride metabolism, apolipoprotein A5 [APOA5] rs651821: apolipoprotein that regulates triglyceride metabolism; [0-6]), (2) LDL-cholesterol-increasing alleles (apolipoprotein B [APOB] rs5742904: main structural apolipoprotein of LDL particles, LDL receptor [LDLR] W23X, LDLR W66G, LDLR W556S: hepatic receptors involved in the clearance of LDL particles from the circulation, proprotein kinase convertase subtilisin/kexin type 9 [PCSK9] rs11591147: regulatory protein that enhances LDL receptor degradation [0-3]), and (3) HDL-cholesterol-lowering alleles (hepatic lipase [LIPC] −480C/T: lipase that facilitates conversion of larger to smaller HDL particles, adenosine triphosphate-binding cassette transporter A1 [ABCA1] N1800H, ABCA1 R2144X: transporter that facilitates cholesterol efflux [0-3]). Genotypes were verified by genotyping of randomly selected samples of each variant by 2 different methods (TaqMan plus sequencing or restriction enzyme assay). Genotype call rates were >99% for all assays as a result of reruns.
Covariates
Covariates were selected based on known or suspected associations with levels of lipoproteins and/or 25(OH)D, 4, 19 with the goal to remove potential contributing pathways by adjustments. Body mass index was derived using measured weight (kg) divided by measured height squared (m 2 ) and selected given the potential positive association between high body mass index and elevated levels of atherogenic lipoproteins and low 25(OH)D levels. 24 Diabetes mellitus was selfreported or defined by nonfasting plasma glucose >11 mmol/L, the use of antidiabetic medication, and hospitalization because of diabetes mellitus (International Classification of Disease-Eighth Revision: 249 and 250; International Classification of Diseases-Tenth Revision: E10, E11, E13, and E14) and selected given the potential positive association between the presence of diabetes mellitus and elevated levels of atherogenic lipoproteins and low 25(OH)D levels. 24 Estimated glomerular filtration rate (mL/min per 1.73 m 2 ) was derived as described 25 and selected given the potential positive association between low estimated glomerular filtration rate and elevated levels of atherogenic lipoproteins and low 25(OH)D levels. Smoking habits (nonsmoker, exsmoker, and current smoker), income status (<100 000DKK, 100 000-400 000DKK, 400 000-600 000DKK, or >600 000DKK), Analyses were by heteroskedasticity robust linear regression with adjustments for age and sex and further additional adjustments for body mass index, systolic blood pressure, estimated glomerular filtration rate, diabetes mellitus, smoking, education, income, physical activity, lipid-lowering therapy, hormone therapy, parity prevention therapy, vitamin supplementation, and alcohol intake. Gray areas describe the 95% confidence interval (CI) of the fitted regression line. These analyses represent 1 in Figure 1 . education (0-14 years), intensity of leisure-time physical activity (0, 2, 2-4, and >4 hours/wk), the use of lipid-lowering therapy (yes/no), hormone therapy (yes/no), parity prevention therapy (yes/no), vitamin supplementation (yes/no), and alcohol intake (unit/wk; 1 unit=12 g of alcohol) were self-reported and selected given potential associations between lifestyle and the use of therapeutic interventions and plasma levels of atherogenic lipoproteins and 25(OH)D. 4, 19 
Statistical Analyses
To account for seasonal variation in plasma 25(OH)D levels, individuals were assigned to percentiles of plasma 25(OH)D levels by month of sample collection. 22 This approach provides a better estimate of the associations between plasma levels of 25(OH)D and lipoproteins because it removes variability in plasma levels of 25(OH)D because of different degrees of sun exposure at different times in Denmark. Nonnormally distributed variables were log-transformed as appropriate. χ 2 test evaluated Hardy-Weinberg equilibrium. Statistical analyses were conducted according to the order of 1 to 3 in Figure 1 .
First, to test whether plasma lipoprotein levels were associated observationally with plasma 25(OH)D levels, heteroskedasticity robust linear regressions were used (Figure 1, 1 ). Analyses were either adjusted for age and sex or multivariably adjusted for age, body mass index, systolic blood pressure, estimated glomerular filtration rate, education, and alcohol intake as continuous variables and sex, diabetes mellitus, smoking, income, leisure-time physical activity, lipid-lowering therapy, hormone therapy, parity prevention therapy, and vitamin supplementation as categorical variables. The assumption of linearity of association was visually tested using a plot of observed versus predicted values; homoscedasticity was visually tested using a plot of residual versus predicted values; and normality of residuals visually tested by boxplot of the residuals, and by a plot of residual versus predicted values or x-variable. No major violations to assumptions of linearity, homoscedasticity, or normality of residuals were observed. Potential effect modifications were investigated by assessing 2-factor interaction terms (eg, remnant cholesterol×sex on 25(OH)D levels) decided a priori, incorporated one at a time, in the multivariably adjusted model using Wald tests. Covariates examined for potential effect modifications were based on known or suspected interaction effects with levels of lipoproteins and 25(OH)D. No significant 2-factor interaction terms were observed.
Second, to test whether genotypes, individually or as allele scores, for lipoproteins or 25(OH)D were associated genetically with corresponding lipoprotein or plasma 25(OH)D levels, Cuzick extension of a Wilcoxon rank-sum test for trend was used (Figure 1 , 2). In these analyses, we thus tested whether the genetic instruments were good instruments for plasma levels.
Third, to test whether genotypes, individually or as allele scores, for lipoproteins were associated genetically with plasma 25(OH)D levels, and the converse, whether genotypes, individually or as allele scores, for plasma 25(OH)D were associated genetically with lipoprotein levels, Cuzick extension of a Wilcoxon rank-sum test for trend was used (Figure 1, 2-3) .
Finally, to test whether there were potential associations between genetically elevated or reduced levels of the different lipoproteins and 25(OH)D levels, instrumental variable analyses using 2-stage least squares regression were applied (Figure 1 , integrating 2 and 3). Genotypes, as allele scores, associated with a specific lipoprotein were included as instruments in both first-and second-stage regressions. The strength of the instrument was evaluated by F-statistics from the first-stage regressions, where an F-statistics >10 has been used to indicate sufficient strength, 15 and by R 2 (%) as a measure of the percentage contribution of allele scores to the variation in plasma levels. Genetic estimates from instrumental variable analyses were compared with estimates from observational analyses using a generalized Hausman test. The same strategy was applied to evaluate the potential associations between genetically reduced levels of 25(OH) D with levels of different lipoproteins although the Wald-type estimator was used given that we had more genotypes than 25(OH)D measurements, and the 95% confidence interval was derived using the Δ method. For lipoproteins levels, we used a doubling/halving in levels because lipoprotein levels were log(2)-transformed to approach the normal distribution, whereas for 25(OH)D levels we used a 50% decrease to reflect approximately a halving of 25(OH)D levels.
Two-sided P values or corresponding 95% confidence intervals (95% CIs) were reported for all aforementioned analyses. Data were analyzed using Stata/SE 12.0. To achieve maximal statistical power, the CGPS and CCHS were combined in a single analysis; however, the results presented were similar within each study separately.
Results
Characteristics of study participants by tertiles of plasma 25(OH)D levels are shown in the Table, illustrating that 25(OH) D levels were associated with most potential confounders, as did levels of lipoproteins (Table IA -IC in the Data Supplement). In contrast, potential confounders were generally equally distributed among genotypes (illustrating that genotypes are largely unconfounded), other than the expected higher use of lipid-lowering therapy among those with genotypes for higher levels of nonfasting remnant and LDL-cholesterol (Table; Table IIA -D in the Data Supplement). DHCR7 and CYP2R1 genotypes for 25(OH)D levels were in linkage equilibrium (R 2 =0%), implying that genetic variants in the 2 genes were completely unrelated; within each gene, the 2 variants each explained 49% of the variation in the other ( Figure I in the Data Supplement). We detected no association of DHCR7 and CYP2R1 allele scores with plasma cholesterol, cortisol, estradiol, and testosterone ( Table III in the Data Supplement). Genetic variants on chromosome 11 shown by genome-wide association studies to be associated with plasma lipoprotein levels, specifically APOA5 rs651821, showed no sign of linkage disequilibrium with DHCR7 and CYP2R1 variants in the HapMap population ( Figure II in the Data Supplement). The genetic variants chosen as instruments for lipoproteins were also unrelated. All genotypes were in Hardy-Weinberg equilibrium.
Plasma Levels of Lipoproteins and 25(OH)D: Observational Associations
The associations between plasma levels of lipoproteins and 25(OH)D are shown in Figure 2 . High plasma levels of nonfasting remnant and LDL-cholesterol were associated with low levels of plasma 25(OH)D, whereas low plasma levels of HDLcholesterol were associated with low levels of plasma 25(OH) D both in age-and sex-adjusted analyses and in multivariably adjusted analyses that included age, body mass index, systolic blood pressure, estimated glomerular filtration rate, sex, diabetes mellitus, smoking, education, income, leisure-time physical activity, lipid-lowering therapy, hormone therapy, parity prevention therapy, vitamin supplementation, and alcohol intake.
In the multivariably adjusted model, plasma 25(OH)D levels were −6.0% (95% CI, −6.5% to −5.5%) and −4.6% (95%−CI, −5.4%, to −3.7%) lower for each doubling of nonfasting remnant and LDL-cholesterol levels, and −1.5%(95% CI, −2.2% to −0.7%) lower for each halving of HDL-cholesterol levels. Higher plasma Lp(a) levels were not associated with plasma 25(OH)D levels in the multivariably adjusted model (Figure 2) .
Test for interactions decided a priori showed that the association between nonfasting remnant cholesterol and 25(OH)D levels was robust with no evidence for effect modification by sex, diabetes mellitus, obesity (body mass index, <30 or ≥30 kg/m 2 ), estimated glomerular filtration rate (<60 or ≥60 mL/ min per 1.73 m 2 ), physical activity, hormone therapy, or vitamin supplementation, incorporated one at a time, in multivariably adjusted analyses that included age, body mass index, systolic blood pressure, estimated glomerular filtration rate, sex, diabetes mellitus, smoking, education, income, leisure-time physical activity, lipid-lowering therapy, hormone therapy, parity prevention therapy, vitamin supplementation, and alcohol intake. Similar findings were observed for LDL and HDL-cholesterol with no significant interaction tests after correction for 21 multiple testing using the Bonferroni method. For nonfasting remnant cholesterol-increasing alleles, 3 to 6 versus 0 to 1 alleles was associated with −2% lower plasma 25(OH)D levels and +15% higher nonfasting remnant cholesterol levels, with small effects on LDL and HDL-cholesterol levels (Figure 3 ). For LDL-cholesterol-increasing alleles, 2 to 3 versus 0 to 1 alleles was associated with −3% lower plasma 25(OH)D levels and +13% higher LDL-cholesterol levels, with small effects on HDL-cholesterol levels. For HDL-cholesterollowering alleles, 2 to 3 versus 0 to 1 alleles was associated with +1% higher plasma 25(OH)D levels and −4% lower HDLcholesterol levels, with small effects on nonfasting remnant cholesterol levels. For 25(OH)D-lowering alleles, 6 to 8 versus 0 to 1 alleles was associated with −10% lower plasma 25(OH)D levels with marginal effects on HDL-cholesterol levels.
Genotypes and Plasma Levels of 25(OH)D and Lipoproteins

Plasma Levels of Lipoproteins and 25(OH)D: Genetic Associations
The potential genetic associations between plasma levels of lipoproteins and 25(OH)D, determined using instrumental variable analyses, are shown in Figure 4 . A doubling in nonfasting remnant cholesterol levels was observationally and genetically associated with −6.0% (95%CI, −6.5% to −5.5%) and −8.9% (95% CI, −15% to −2.3%) lower plasma 25(OH)D levels. For LDL-cholesterol levels, corresponding values were −4.6% (95% CI, −5.4% to −3.7%) observationally and −11% (95% CI, −29%, +6.9%) genetically. In contrast, a halving of HDL-cholesterol levels was observationally associated with −1.5% (95% CI, −2.2% to −0.7%) lower, but genetically associated with +20% (95% CI, +7.4% to +34%) higher plasma 25(OH)D levels.
A 50% decrease in plasma 25(OH)D levels was observationally associated with +15% (95% CI, +14% to +17%) and +3.8% (95% CI, +3.1% to +4.5%) higher plasma levels of nonfasting remnant and LDL-cholesterol ( Figure 5 ). There were, however, no associations between 25(OH)D-lowering alleles for either nonfasting remnant or LDL-cholesterol. Finally, a 50% decrease in plasma 25(OH)D levels was observationally and genetically associated with −1.1% (95% CI, −1.7% to −0.5%) and −6.0% (95% CI, −10% to −2.3%) lower HDL-cholesterol levels. Continuous variables are summarized as median and interquartile range. 25(OH)D indicates 25-hydroxyvitamin D; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and NS: not statistically significant after adjustment for 15 multiple comparisons, using the Bonferroni method (required P value for significance: P=0.05/15=0.003).
Table. Characteristics of Individuals From the General Population by Tertiles of Seasonally Adjusted Plasma 25(OH)D Levels
*P values were determined using Cuzick nonparametric trend test. †Women only. ‡1 unit=12 g of alcohol.
§A small difference in alcohol intake for the remnant cholesterol genotypes is likely due to chance
Discussion
Using genetic instruments, we found an association between genetically elevated nonfasting remnant cholesterol levels and low plasma 25(OH)D levels, whereas genetically reduced HDLcholesterol was not associated with low plasma 25(OH)D levels.
These findings are novel, provide key insights into the mechanisms underlying the observed associations between elevated atherogenic lipoproteins and low plasma 25(OH)D levels, and offer an explanation for the lack of clinically meaningful changes in lipoprotein levels with vitamin D supplements to date. 7, [9] [10] [11] [12] [13] Of interest, we have previously demonstrated that elevated nonfasting remnant cholesterol levels, like elevated LDL-cholesterol levels, are genetically related to ischemic heart disease, 18, 20 and that elevated nonfasting remnant cholesterol levels are genetically associated with increased low-grade inflammation. 19 Despite the application of the Mendelian randomization approach in a large cohort, the present study has not definitively answered the questions asked, particularly with relation to causality. For many situations, including ones involving biomarkers such as this study, there are likely to be multiple pathways affecting the biomarkers. Such a complex situation can indeed render the question of which measure is cause and which is effect difficult.
It is noteworthy that the biological mechanism that governs a negative association between cholesterol levels and 25(OH)D levels has not been established. Nonetheless, mechanistically, the present findings can be theoretically explained considering that cholesterol and vitamin D share a biosynthetic pathway. 26, 27 Consequently, an upregulated cholesterol biosynthesis may result in a downregulated vitamin D biosynthesis and conversely, a downregulated vitamin D biosynthesis may result in an upregulated cholesterol biosynthesis, explaining the observed inverse association between plasma levels of atherogenic lipoproteins (ie, remnant and LDL-cholesterol) and 25(OH)D. In addition, recent in vitro studies suggest that absorption of vitamin D not only is by passive diffusion but also involves intestinal lipid transporters, dependent on bile salts availability, and is impaired dose dependently with stepwise increases in cholesterol levels. 28 These observations further support a potential regulatory role for genetically elevated atherogenic lipoproteins levels on low plasma 25(OH)D levels.
A key focus in vitamin D research during the past decade has been on its potential lipid-lowering effects, with the indirect aim to explain the association between low plasma 25(OH)D levels and high cardiovascular risk observed in epidemiological studies. [1] [2] [3] To the contrary, our findings implicate that genetically elevated nonfasting remnant cholesterol levels is a determinant of low plasma 25(OH)D levels, rather than genetically low plasma 25(OH)D levels being the determinant of elevated nonfasting remnant cholesterol. Thus, an explanation for the association of low plasma 25(OH)D levels with high cardiovascular risk may be that plasma 25(OH)D is simply a marker of elevated atherogenic lipoproteins 29 (ie, elevated nonfasting remnant cholesterol and possibly elevated LDL-cholesterol according to the present study). Evidence for this notion also comes from statin studies [30] [31] [32] : in these studies, increases in plasma 25(OH)D levels in concert with the decreases in plasma atherogenic lipoprotein levels have been observed, which have been attributed to a potential independent effect of statins on vitamin D biosynthesis and consequently, a synergistic lipidlowering effect by endogenous vitamin D. [30] [31] [32] However, we did not observe an association between genetically reduced 25(OH) D levels and nonfasting remnant or LDL-cholesterol levels. The alternative interpretation whereby statins reduce atherogenic lipoproteins, which in turn raise plasma 25(OH)D levels is, therefore, plausible. Furthermore, a recent large prospective study reported no appreciable changes in plasma lipoprotein levels with vitamin D repletion (defined as 25(OH)D levels <20 ng/mL at baseline and ≥30 ng/mL but ≤100 ng/mL at a subsequent visit, without the use of vitamin D supplementation/lipidlowering therapy). 33 This is consistent with our study findings.
Unexpectedly, we found an association between genetically low HDL-cholesterol levels and high 25(OH)D levels, the opposite of observational associations between low HDLcholesterol and low 25(OH)D levels. We speculate that the discrepancy may relate to the well-known association between low HDL-cholesterol and high remnant cholesterol 18 and increased cardiovascular risk. Therefore, we would speculate that the association between low HDL-cholesterol and low 25(OH)D levels is secondary and driven by the association between high remnant cholesterol and low 25(OH)D levels. This finding is supported by statin studies showing that decreases in plasma atherogenic lipoprotein levels and increases in plasma 25(OH) D levels with statins have not been consistently coupled with increases in HDL-cholesterol levels. [30] [31] [32] Furthermore, elevated HDL-cholesterol levels per se may not confer cardioprotection, as suggested by Mendelian randomization studies and clinical end point trials. 18, [34] [35] [36] [37] [38] [39] Nonetheless, our finding should be interpreted in context with the inherent limitations of the Mendelian randomization approach. Therefore, additional studies to interrogate the association between genetically low HDL-cholesterol levels and plasma 25(OH)D levels are required.
Potential limitations of the Mendelian randomization approach includes pleiotropy where the genetic variant is not exclusively affecting the risk factor (eg, lipoprotein/25(OH)D levels), linkage disequilibrium where there is association between the genetic variants used as instruments with other genetic variants and the potential presence of unmeasured or unknown confounding factors. [14] [15] [16] Therefore, we have endeavored to interpret and discuss our findings with these limitations in mind. First, it is without doubt that lipoprotein metabolism is complex. Furthermore, highly informative assessments of the intricate pathways and lipoprotein subclasses within the lipoprotein system may have revealed varying degrees of pleiotropy in the genetic variants affecting lipoprotein levels in vivo. 40 Consequently, we acknowledge that it is a challenge, if not an impossibility, to identify genetics instruments completely without pleiotropic effects in this context. The use of allele scores, where >1 variant on different genes and chromosomes can be examined collectively, nevertheless, minimized the likelihood of pleiotropy in our study even though it may not have completely avoided it. 40, 41 We also propose that although our calculation of nonfasting remnant cholesterol is simple, relative to the detailed analyses of pathways and lipoprotein subclasses, it is the simplicity of our calculation that allows nonfasting remnant cholesterol to be clinically useful without entailing additional expenses, specialized equipment, or complicated interpretation. 40, 41 In addition, we assessed and found no associations between genetic variants in DHCR7 or CYP2R1 with levels of cholesterol or steroid hormones. This, together with the use of allele scores of 25(OH) D-lowering alleles, further lessened the likelihood that pleotropic effects alone should explain our results. Second, we assessed and found that the DHCR7 and CYP2R1 genetic variants were not in linkage disequilibrium with each other or with APOA5 rs651821, the only other variant located on chromosome 11. There are also no reports to suggest that DHCR7 and CYP2R1 genetic variants were in linkage disequilibrium with genetic variants for lipoproteins or that the genetic variants used as instruments for lipoprotein levels were in linkage disequilibrium. Therefore, it should be unlikely that our findings were confounded by linkage disequilibrium significantly. Third, we explored and demonstrated that potential confounders were generally equally distributed among genotypes. Therefore, it would seem reasonable to presume nointeractions and no residual confounding in our study although this is based on the assumption that unmeasured confounders behave similarly to measured confounders. We, nevertheless, acknowledge that it is possible that there may be unmeasured confounders and consequently not all pathways accounted for by adjustment in this study. Finally, because of the abovementioned limitations and the power requirements of Mendelian randomization studies, we cannot discount the possibility that we overlooked smaller genetic associations in our study.
Strengths of our study include a large sample size and the application of a Mendelian randomization approach to examine genetic associations between plasma lipoprotein and 25(OH)D levels. In addition, the genetic instruments used were statistically strong (F>>10). Finally, all participants were white and of Danish decent, largely eliminating population admixture as a potential problem. We, nonetheless, acknowledge that even in a homogenous population, we cannot completely rule out hidden population strata.
In conclusion, our study illustrated that genetically elevated nonfasting remnant cholesterol is associated with low 25(OH) D levels, whereas genetically reduced HDL-cholesterol was not associated with low 25(OH)D levels. These findings suggest that low 25(OH)D levels observationally is simply a marker for elevated atherogenic lipoproteins, and thus question a role for vitamin D supplementation in the prevention of cardiovascular disease. Certainly, our data give emphasis toward a more conservative approach 29 to use vitamin D supplementation as a lipid-lowering intervention.
